Communication To Health Care Professionals Archives - Page 7 of 9

17 Aug Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones

Posted at 12:47h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you about the risk of mitral and aortic regurgitation that should be taken into consideration when prescribing oral fluoroquinolone antibiotics. ...

17 Aug Sandoz and Novartis: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy

Posted at 12:45h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of cleft lip and/or cleft palate following the use of ZOFRAN® (ondansetron) during the first 12 weeks of pregnancy. ...

17 Aug Ondansetron: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy

Posted at 12:45h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of an increased risk of cleft lip and/or cleft palate following the use of ondansetron during the first 12 weeks of pregnancy....

17 Aug Tyrosine kinase inhibitors

Posted at 12:41h in

The pharmaceutical companies mentioned below, in collaboration with South African Health Products Regulatory Authority (SAHPRA), wish to inform you of the class related cerebrovascular adverse events reported with the use of tyrosine kinase inhibitor (TKI) containing medicines. The Professional Information (PI) and Patient Information Leaflet...

17 Aug Fluoropyrimidine containing medicines and related substances: Increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency

Posted at 12:38h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you of the requirement of pre-testing to identify patients at increased risk of severe toxicity due to fluoropyrimidine containing medicines....

17 Aug Risk of dopamine dysregulation syndrome (DDS) associated with the use of dopaminergic medicines used for the treatment of Parkinson’s disease (PD).

Posted at 12:37h in

The pharmaceutical companies mentioned below, in collaboration with South African Health Products Regulatory Authority (SAHPRA), wish to inform you of the risk of dopamine dysregulation syndrome (DDS) associated with the chronic use of dopaminergic medicines used for the treatment of Parkinson’s disease. The Professional Information...

17 Aug Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

Posted at 12:36h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Products (Pty) Ltd would like to inform you of the risk of Severe Cutaneous Adverse Reactions (SCARs) and immune-related myositis associated with the use of Tecentriq® (azeolizumab)....

17 Aug Dopaminergic medicines used in the treatment of parkinson’s disease: Risk of Dopamine dysregulation syndrome

Posted at 12:34h in

2020 Oct...

17 Aug Diphenhydramine-containing Medicines

Posted at 12:32h in

The South African Health Products Regulatory Authority (SAHPRA) wishes to alert healthcare professionals about the risk of serious heart problems, seizures, coma and death associated with the use of high doses of diphenhydramine-containing medicines. An online challenge known as “the Benadryl Challenge” has recently been...

17 Aug Eltroxin New Formulation (25 Mcg, 50 Mcg, 75 Mcg, 100 And 200 Mcg Tablets: Increased Adverse Events Reports And Requirement For Patient Therapeutic Monitoring By Healthcare Professionals.

Posted at 12:31h in

Pharmacare, in consultation with the South African Health Products Regulatory Authority (SAHPRA) would like to warn healthcare professionals about an increase of adverse events/side effects associated with the introduction of Eltroxin New Formulation® and a call for therapeutic drug monitoring in patients using or switched...

Archive